Effect of Empagliflozin on the Reactivity of Mesenteric Arteries and Skin Microvessels in Rats Treated with Doxorubicin

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

The study assessed the potential protective effect of empagliflozin (EMPA) on the functional state of various types of vessels in Wistar rats that received a single injection of the anthracycline antibiotic doxorubicin (DOX), used clinically as a chemotherapeutic agent for cancer. The rats were divided into 3 groups, 15 animals in each group. Rats in the DOX group were administered DOX (4 mg/kg) once, while animals in the DOX+EMPA group after a single administration of DOX (4 mg/kg) received EMPA (1 mg/kg) daily through a tube for 5 weeks. The control group consisted of intact animals. After 4 weeks of the experiment, the rats were examined for the initial skin microcirculation indices and their changes after iontophoresis of acetylcholine (ACh) and sodium nitroprusside (NP) using Laser Doppler Flowmetry (LDF). One week after LDF, the mesenteric artery dilation value was analyzed by assessing the changes in vessel diameter before and after the action of ACh and NP, without blockers and under conditions of preliminary incubation of vessels with the NO synthase blocker L-NAME. In the control group rats, ACh iontophoresis caused an increase in perfusion intensity by 78.5%, in the DOX group the change was less pronounced (by 55.2%). EMPA prevented a decrease in the skin microvessel response to ACh, the perfusion index in rats of the DOX+EMPA group increased by 82.8%. The increase in the microcirculation index after NP iontophoresis in the DOX+EMPA group did not differ from the control, and in the DOX group it was significantly lower. ACh-induced dilation of the mesenteric arteries of the DOX group was 24.3% lower than in the control rats. The use of EMPA in rats that received DOX improved arterial reactivity. Compared with the reactivity of vessels without blockers, incubation of vessels with L-NAME reduced the amplitude of dilation under the action of ACh in all groups, but a less pronounced change was observed in the DOX group (45.6%). When using EMPA, the differences in the relaxation amplitude before and after NO synthase blockade increased (54.4%), but did not reach the control (64.1%). Conclusion. DOX leads to a decrease in the reactivity of various types of vessels to the action of vasodilators, in particular, ACh and NP. The use of EMPA has a protective effect in animals after the introduction of DOX, improving the dilation of the mesenteric arteries and vessels of the skin microcirculatory bed. It is possible that the effect of EMPA is associated with an improvement in the efficiency of NO-dependent vasorelaxation pathways, the disruption of which is observed upon the introduction of DOX.

Full Text

Restricted Access

About the authors

G. T. Ivanova

Pavlov Institute of Physiology of the RAS

Author for correspondence.
Email: ivanovagt@infran.ru
Russian Federation, Saint Petersburg

O. N. Beresneva

First Pavlov Saint Petersburg State Medical University

Email: ivanovagt@infran.ru
Russian Federation, Saint Petersburg

S. V. Okovity

Saint Petersburg State Chemical and Pharmaceutical University

Email: ivanovagt@infran.ru
Russian Federation, Saint Petersburg

A. N. Kulikov

First Pavlov Saint Petersburg State Medical University

Email: ivanovagt@infran.ru
Russian Federation, Saint Petersburg

References

  1. Ma J, Lu J, Shen P, Zhao X, Zhu H (2023) Comparative efficacy and safety of sodium-glucose cotransporter 2 inhibitors for renal outcomes in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis. Ren Fail 45(2): 2222847. https://doi.org/10.1080/0886022X.2023.2222847
  2. Vrhovac I, Balen Eror D, Klessen D, Burger C, Breljak D, Kraus O, Radović N, Jadrijević S, Aleksic I, Walles T, Sauvant C, Sabolić I, Koepsell H (2015) Localizations of Na+-d-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart. Pflügers Arch-Eur J Physiol 467: 1881–1898. https://doi.org/10.1007/s00424-014-1619-7
  3. Salvatore T, Carbonara O, Cozzolino D, Torella R, Nasti R, Lascar N, Sasso FC (2011) Kidney in diabetes: From organ damage target to therapeutic target. Curr Drug Metab 12: 658–666. https://doi.org/10.2174/138920011796504509
  4. Chao EC, Henry RR (2010) SGLT2 inhibition–A novel strategy for diabetes treatment. Nat Rev Drug Discov 9: 551–559. https://doi.org/10.1038/nrd3180
  5. Rieg T, Masuda T, Gerasimova M, Mayoux E, Platt K, Powell DR, Thomson SC, Koepsell H, Vallon (2014) Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia. Am J Physiol 306: F188–F193. https://doi.org/10.1152/ajprenal.00518.2013
  6. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE (2015) Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 373(22): 2117–2128. https://doi.org/10.1056/NEJMoa1504720
  7. Younis F, Leor J, Abassi Z, Landa N, Rath L, Hollander K, Naftali-Shani N, Rosenthal T (2018) Beneficial effect of the SGLT2 inhibitor empagliflozin on glucose homeostasis and cardiovascular parameters in the cohen rosenthal diabetic hypertensive (CRDH) rat. J Cardiovasc Pharmacol Ther 23(4): 358–71. https://doi.org/10.1177/1074248418763808
  8. Li C, Zhang J, Xue M, Li X, Han F, Liu X, Xu L, Lu Y, Cheng Y, Li T, Yu X, Sun B, Chen L (2019) SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol 18(1): 15. https://doi.org/10.1186/s12933-019-0816-2
  9. Inzucchi SE, Kosiborod M, Fitchett D, Wanner C, Hehnke U, Kaspers S, George JT, Zinman B (2018) Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control Circulation. Circulation 138(17): 1904–1907. https://doi.org/10.1161/CIRCULATIONAHA.118.035759
  10. Приходько ВА, Оковитый СВ, Куликов АН (2023) Глифлозины при неалкогольной жировой болезни печени: перспективы применения за границами диабета, кардио- и нефропротекции. Терапия 9(7): 130–141. [Prikhodko VA, Okovity SV, Kulikov AN (2023) Gliflozins in non-alcoholic fatty liver disease: Perspectives of use outside diabetes, cardiac and nephroprotection. Therapy 9(7): 130–141. (In Russ)]. https://dx.doi.org/10.18565/therapy.2023.7.130–141
  11. Lee HC, Shiou YL, Jhuo SJ, Chang CY, Liu PL, Jhuang WJ, Dai ZK, Chen WY, Chen YF, Lee AS (2019) The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats. Cardiovasc Diabetol 18(1): 45. https://doi.org/10.1186/s12933-019-0849-6
  12. Куликов АН, Краснова МВ, Ивкин ДЮ, Карпов АА, Кашина Е, Оковитый СВ, Демакова НВ (2021)Эффективность эмпаглифлозина при экспериментальной хронической сердечной недостаточности в условиях нормогликемии. Кардиология: новости, мнения, обучение 9(1): 9–16. [Kulikov AN, Krasnova MV, Ivkin DYu, Karpov AA, Kaschina E, Okovityy SV, Демакова НВ (2021) Efficacy of empagliflozine in experimental chronic heart failure in normoglycemiaobucheniye. Cardiology: News, opinions, training 9(1): 9–16. (In Russ)]. https://doi.org/10.33029/2309-1908-2021-9-1-9-16
  13. Kusaka H, Koibuchi N, Hasegawa Y, Ogawa H, Kim-Mitsuyama S (2016) Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome. Cardiovasc Diabetol 15(1): 157. https://doi.org/10.1186/s12933-016-0473-7
  14. Park SH, Farooq MA, Gaertner S, Bruckert C, Qureshi AW, Lee HH, Benrahla D, Pollet B, Stephan D, Ohlmann P, Lessinger JM, Mayoux E, Auger C, Morel O, Schini-Kerth VB (2020) Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat. Cardiovasc Diabetol 19(1): 19. https://doi.org/10.1186/s12933-020-00997-7
  15. Salvatore T, Caturano A, Galiero R, Di Martino A, Albanese G, Vetrano E, Sardu C, Marfella R, Rinaldi L, Sasso FC (2021) Cardiovascular Benefits from Gliflozins: Effects on Endothelial Function. Biomedicines 9(10): 1356. https://doi.org/10.3390/biomedicines9101356
  16. Salvatore T, Galiero R, Caturano A, Rinaldi L, Di Martino A, Albanese G, Di Salvo J, Epifani R, Marfella R, Docimo G, Lettieri M, Sardu C, Sasso FC (2022) An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors. Int J Mol Sci 23(7): 3651. https://doi.org/10.3390/ijms23073651
  17. Sabatino J, De Rosa S, Tammè L, Iaconetti C, Sorrentino S, Polimeni A, Mignogna C, Amorosi A, Spaccarotella C, Yasuda M, Indolfi C (2020) Empagliflozin prevents doxorubicin-induced myocardial dysfunction. Cardiovasc Diabetol 19(1): 66. https://doi.org/10.1186/s12933-020-01040-5
  18. Hasan A, Hasan R (2021) Empagliflozin Relaxes Resistance Mesenteric Arteries by Stimulating Multiple Smooth Muscle Cell Voltage-Gated K+ (KV) Channels. Int J Mol Sci 22(19): 10842. https://doi.org/10.3390/ijms221910842
  19. Adingupu DD, Göpel SO, Grönros J, Behrendt M, Sotak M, Miliotis T, Dahlqvist U, Gan LM, Jönsson-Rylander AC (2019) SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob(-/-) mice. Cardiovasc Diabetol 18(1): 16. https://doi.org/10.1186/s12933-019-0820-6
  20. Tan C, Zeng J, Wu G, Zheng L, Huang M, Huang X (2021) Xinshuitong Capsule extract attenuates doxorubicin-induced myocardial edema via regulation of cardiac aquaporins in the chronic heart failure rats. Biomed Pharmacother 144: 112261. https://doi.org/10.1016/j.biopha.2021.112261
  21. He H, Wang L, Qiao Y, Zhou Q, Li H, Chen S, Yin D, Huang Q, He M (2020) Doxorubicin Induces Endotheliotoxicity and Mitochondrial Dysfunction via ROS/eNOS/NO Pathway. Front Pharmacol 10: 1531. https://doi.org/10.3389/fphar.2019.01531
  22. Ivanova GT (2022) Effect of Doxorubicin on the Reactivity of Rat Mesenteric Arteries. J Evol Biochem Phys 58(6): 1914–1925. https://doi.org/10.1134/S0022093022060205
  23. Wen J, Zhang L, Liu H, Wang J, Li J, Yang Y, Wang Y, Cai H, Li R, Zhao Y (2019) Salsolinol Attenuates Doxorubicin-Induced Chronic Heart Failure in Rats and Improves Mitochondrial Function in H9c2 Cardiomyocytes. Front Pharmacol 10: 1135. https://doi.org/10.3389/fphar.2019.01135
  24. Huang C, Qiu S, Fan X, Jiao G, Zhou X, Sun M, Weng N, Gao S, Tao X, Zhang F, Chen W (2021) Evaluation of the effect of Shengxian Decoction on doxorubicin-induced chronic heart failure model rats and a multicomponent comparative pharmacokinetic study after oral administration in normal and model rats. Biomed Pharmacother 144: 112354. https://doi.org/10.1016/j.biopha.2021.112354
  25. Luu AZ, Chowdhury B, Al-Omran M, Teoh H, Hess DA, Verma S (2018) Role of Endothelium in Doxorubicin-Induced Cardiomyopathy. JACC Basic Transl Sci 3(6): 861–870. https://doi.org/10.1016/j.jacbts.2018.06.005
  26. Zhang Q, Malik P, Pandey D, Gupta S, Jagnandan D, Belin de Chantemele E, Banfi B, Marrero MB, Rudic RD, Stepp DW, Fulton DJ (2008) Paradoxical activation of endothelial nitric oxide synthase by NADPH oxidase. Arterioscler Thromb Vasc Biol 28(9): 1627–1633. https://doi.org/0.1161/ATVBAHA.108.168278
  27. Seo MS, Jung HS, An JR, Kang M, Heo R, Li H, Han ET, Yang SR, Cho EH, Bae YM, Park WS (2020) Empagliflozin dilates the rabbit aorta by activating PKG and voltage-dependent K+ channels. Toxicol Appl Pharmacol 403: 115153. https://doi.org/10.1016/j.taap.2020.115153
  28. Jackson WF (2018) K(V) channels and the regulation of vascular smooth muscle tone. Microcirculation 25: e12421. https://doi.org/10.1111/micc.12421
  29. Tamargo J, Caballero R, Gómez R, Valenzuela C, Delpón E (2004) Pharmacology of cardiac potassium channels. Cardiovasc Res 62(1): 9–33. https://doi.org/10.1016/j.cardiores.2003.12.026
  30. Quagliariello V, De Laurentiis M, Rea D, Barbieri A, Monti MG, Carbone A, Paccone A, Altucci L, Conte M, Canale ML, Botti G, Maurea N (2021) The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. Cardiovasc Diabetol20(1): 150. https://doi.org/10.1186/s12933-021-01346-y
  31. Lin R, Peng X, Li Y, Wang X, Liu X, Jia X, Zhang C, Liu N, Dong J (2024) Empagliflozin attenuates doxorubicin-impaired cardiac contractility by suppressing reactive oxygen species in isolated myocytes. Mol Cell Biochem 479(8): 2105–2118. https://doi.org/10.1007/s11010-023-04830-z
  32. Mele D, Tocchetti CG, Pagliaro P, Madonna R, Novo G, Pepe A, Zito C, Maurea N, Spallarossa P (2016) Pathophysiology of anthracycline cardiotoxicity. J Cardiovasc Med 17(Suppl 1): e3–e11. https://doi.org/10.2459/JCM.0000000000000378
  33. Rea D, Coppola C, Barbieri A, Monti MG, Misso G, Palma G, Bimonte S, Zarone MR, Luciano A, Liccardo D, Maiolino P, Cittadini A, Ciliberto G, Arra C, Maurea N (2016) Strain analysis in the assessment of a mouse model of cardiotoxicity due to chemotherapy: Sample for preclinical research. In Vivo 30(3): 279–290.
  34. Zou R, Shi W, Qiu J, Zhou N, Du N, Zhou H, Chen X, Ma L (2022) Empagliflozin attenuates cardiac microvascular ischemia/reperfusion injury through improving mitochondrial homeostasis. Cardiovasc Diabetol 21(1): 106. https://doi.org/10.1186/s12933-022-01532-6.
  35. Soares RN, Ramirez-Perez FI, Cabral-Amador FJ, Morales-Quinones M, Foote CA, Ghiarone T, Sharma N, Power G, Smith JA, Rector RS, Martinez-Lemus LA, Padilla J, Manrique-Acevedo C (2022) SGLT2 inhibition attenuates arterial dysfunction and decreases vascular F-actin content and expression of proteins associated with oxidative stress in aged mice. Geroscience 44(3): 1657–1675. https://doi.org/10.1007/s11357-022-00563-x
  36. Uthman L, Li X, Baartscheer A, Schumacher CA, Baumgart P, Hermanides J, Preckel B, Hollmann MW, Coronel R, Zuurbier CJ, Weber NC (2022) Empagliflozin reduces oxidative stress through inhibition of the novel inflammation/NHE/[Na(+)](c)/ROS-pathway in human endothelial cells. Biomed Pharmacother 146: 112515. https://doi.org/10.1016/j.biopha.2021.112515
  37. Wang J, Huang X, Liu H, Chen Y, Li P, Liu L, Li J, Ren Y, Huang J, Xiong E, Tian Z, Dai X (2022) Empagliflozin ameliorates diabetic cardiomyopathy via attenuating oxidative stress and improving mitochondrial function. Oxid Med Cell Longev 2022: 1122494. https://doi.org/10.1155/2022/1122494
  38. Tarbell JM, Cancel LM (2016) The glycocalyx and its significance in human medicine. J Intern Med 280(1): 97–113. https://doi.org/10.1111/joim.12465
  39. Cooper S, Teoh H, Campeau MA, Verma S, Leask RL (2019) Empagliflozin restores the integrity of the endothelial glycocalyx in vitro. Mol Cell Biochem 459(1–2): 121–130. https://doi.org/10.1007/s11010-019-03555-2

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Effect of empagliflozin on left ventricular mass index (IMLV) and myocardial mass index (IMM) in rats after doxorubicin administration. Experimental groups: control - control group, DOX - animals that received a single 4 mg/kg doxorubicin, DOX + EMPA - animals that received a single 4 mg/kg doxorubicin and daily 1 mg/kg empagliflozin. Data are presented as mean ± standard error. p - significance of differences between groups.

Download (81KB)
Indexing metadata
3. Fig. 2. Initial microcirculation index in the skin of rats of experimental groups. On the ordinate axis: microcirculation index, perfusion units (PU). Experimental groups: control - control group, DOX - animals that received once 4 mg/kg doxorubicin, DOX + EMPA - animals that received once 4 mg/kg doxorubicin and daily 1 mg/kg empagliflozin. Data are presented as mean ± standard error.

Download (50KB)
Indexing metadata
4. Fig. 3. Calculated value of endothelial (ET), neurogenic (NT) and myogenic (MT) vascular tone of the rat skin microcirculatory channel. On the ordinate axis - tonus value, units. Experimental groups: control - control group, DOX - animals that received 4 mg/kg doxorubicin once, DOX + EMPA - animals that received 4 mg/kg doxorubicin once and 1 mg/kg empagliflozin daily. Data are presented as mean ± standard error. p - significance of differences between groups.

Download (82KB)
Indexing metadata
5. Fig. 4. Mean microcirculation index in rat skin after ionophoresis of acetylcholine solution (ACh) and sodium nitroprusside (NP). On the ordinate axis: microcirculation index, perfusion units (PU). Experimental groups: control - control group, DOX - rats that received doxorubicin, DOX + EMPA - rats that received doxorubicin and empagliflozin treatment.

Download (74KB)
Indexing metadata
6. Fig. 5. Relaxation of rat mesenteric arteries under the action of sodium nitroprusside. On the axis of ordinates - amplitude of dilatation of mesenteric arteries precontracted by phenylephrine (1 × 10-6 mol/l) during sodium nitroprusside (NP, 1 × 10-6 mol/l) administration, expressed as % of the amplitude of constriction on phenylephrine. Experimental groups: control - control group, DOX - rats that received doxorubicin, DOX + EMPA - rats that received doxorubicin and empagliflozin treatment. Data are presented as mean value ± standard error. p - significance of differences between groups.

Download (60KB)
Indexing metadata
7. Fig. 6. Acetylcholine-induced dilatation of rat mesenteric arteries precontracted by phenylephrine, cumulative effect. (a) - amplitude of dilatation of mesenteric arteries during acetylcholine action (ACh): abscissa axis - logarithm of acetylcholine concentration, ordinate axis - amplitude of relaxation expressed as a percentage of the contraction amplitude to phenylephrine (1 x 10-6 mol/L); (b) - area under the curve for acetylcholine: on the ordinate axis is the area under the curve of acetylcholine concentration-dependent dilatation amplitude, units. units. Experimental groups: control - control group, DOX - rats that received doxorubicin, DOX + EMPA - rats that received doxorubicin and empagliflozin treatment. Data are presented as mean value ± standard error. p - significance of differences between groups.

Download (143KB)
Indexing metadata
8. Fig. 7. Acetylcholine-induced dilatation of phenylephrine-pretreated rat mesenteric arteries in the absence of blockers and after incubation of vessels with L-NAME (1 × 10-4 mol/L). Abscissa axis: amplitude of dilatation of mesenteric arteries precontracted by phenylephrine (1 × 10-6 mol/L) under the action of acetylcholine (1 × 10-5 mol/L) expressed as a percentage of the amplitude of constriction to phenylephrine. Experimental groups: control - control group, DOX - rats that received doxorubicin, DOX + EMPA - rats that received doxorubicin and empagliflozin treatment. Data are presented as mean value ± standard error. p - significance of differences between groups.

Download (98KB)
Indexing metadata

Copyright (c) 2025 Russian Academy of Sciences

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».